ANDA 203246, held by Univ Tx Md Anderson. Fludeoxyglucose F-18.
As of Nov 16, 2026, ANDA 203246 (Fludeoxyglucose F18), held by Univ Tx Md Anderson, was first approved by FDA on Jan 13, 2014, with 1 approved supplement and 0 published complete response letters.
1. INDICATIONS AND USAGE Fludeoxyglucose F18 Injection is indicated for positron emission tomography (PET) imaging in the following settings: Fludeoxyglucose F18 Injection is
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 13, 2014 | Original application | Approved | None posted |
| Fludeoxyglucose F1820-150mCi/ML · injectable;intravenous | Fludeoxyglucose F-18 | Rx |
| Fludeoxyglucose F1820-300mCi/ML · injectable;intravenous | Fludeoxyglucose F-18 | Rx |
| Jun 9, 2021 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 13, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters